T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.

ESMO Open · 2021 · PMC8047485 · PMID 33819752

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

marginally non-significantP = 0.052so close (0.05 < p ≤ 0.1)

The presence of brain metastases at baseline was associated with a marginally non-significant worse PFS ( P = 0.052) and a significantly worse OS, independently from treatment and other covariates ( P = 0.043).

also in 1,493 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.